Phase II study of high-dose tamoxifen (NSC-180973) in patients with disseminated malignant melanoma

E. T. Creagan, J. N. Ingle, D. L. Ahmann, S. J. Green

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Seventeen patients with disseminated malignant melanoma received a daily oral regimen of tamoxifen 100 mg/m 2. All patients had prior chemotherapy and predominantly visceral involvement. None of the patients had an objective regression and most (71%) had progressive disease at the time of first reassessment. Moderate to severe nausea occurred in 24% of patients. In the dose and schedule used in this study, tamoxifen is ineffective in patients with advanced malignant melanoma and prior chemotherapy exposure.

Original languageEnglish (US)
Pages (from-to)1353-1354
Number of pages2
JournalCancer
Volume49
Issue number7
StatePublished - 1982

Fingerprint

Tamoxifen
Melanoma
Drug Therapy
Nausea
Appointments and Schedules

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Creagan, E. T., Ingle, J. N., Ahmann, D. L., & Green, S. J. (1982). Phase II study of high-dose tamoxifen (NSC-180973) in patients with disseminated malignant melanoma. Cancer, 49(7), 1353-1354.

Phase II study of high-dose tamoxifen (NSC-180973) in patients with disseminated malignant melanoma. / Creagan, E. T.; Ingle, J. N.; Ahmann, D. L.; Green, S. J.

In: Cancer, Vol. 49, No. 7, 1982, p. 1353-1354.

Research output: Contribution to journalArticle

Creagan, ET, Ingle, JN, Ahmann, DL & Green, SJ 1982, 'Phase II study of high-dose tamoxifen (NSC-180973) in patients with disseminated malignant melanoma', Cancer, vol. 49, no. 7, pp. 1353-1354.
Creagan, E. T. ; Ingle, J. N. ; Ahmann, D. L. ; Green, S. J. / Phase II study of high-dose tamoxifen (NSC-180973) in patients with disseminated malignant melanoma. In: Cancer. 1982 ; Vol. 49, No. 7. pp. 1353-1354.
@article{c9a3e30f60354269b1fd04a36ba965fc,
title = "Phase II study of high-dose tamoxifen (NSC-180973) in patients with disseminated malignant melanoma",
abstract = "Seventeen patients with disseminated malignant melanoma received a daily oral regimen of tamoxifen 100 mg/m 2. All patients had prior chemotherapy and predominantly visceral involvement. None of the patients had an objective regression and most (71{\%}) had progressive disease at the time of first reassessment. Moderate to severe nausea occurred in 24{\%} of patients. In the dose and schedule used in this study, tamoxifen is ineffective in patients with advanced malignant melanoma and prior chemotherapy exposure.",
author = "Creagan, {E. T.} and Ingle, {J. N.} and Ahmann, {D. L.} and Green, {S. J.}",
year = "1982",
language = "English (US)",
volume = "49",
pages = "1353--1354",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "7",

}

TY - JOUR

T1 - Phase II study of high-dose tamoxifen (NSC-180973) in patients with disseminated malignant melanoma

AU - Creagan, E. T.

AU - Ingle, J. N.

AU - Ahmann, D. L.

AU - Green, S. J.

PY - 1982

Y1 - 1982

N2 - Seventeen patients with disseminated malignant melanoma received a daily oral regimen of tamoxifen 100 mg/m 2. All patients had prior chemotherapy and predominantly visceral involvement. None of the patients had an objective regression and most (71%) had progressive disease at the time of first reassessment. Moderate to severe nausea occurred in 24% of patients. In the dose and schedule used in this study, tamoxifen is ineffective in patients with advanced malignant melanoma and prior chemotherapy exposure.

AB - Seventeen patients with disseminated malignant melanoma received a daily oral regimen of tamoxifen 100 mg/m 2. All patients had prior chemotherapy and predominantly visceral involvement. None of the patients had an objective regression and most (71%) had progressive disease at the time of first reassessment. Moderate to severe nausea occurred in 24% of patients. In the dose and schedule used in this study, tamoxifen is ineffective in patients with advanced malignant melanoma and prior chemotherapy exposure.

UR - http://www.scopus.com/inward/record.url?scp=0020060187&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020060187&partnerID=8YFLogxK

M3 - Article

VL - 49

SP - 1353

EP - 1354

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 7

ER -